Nabriva Therapeutics Plc

NASDAQ:NBRV   3:59:27 PM EDT
0.44
-0.05 (-9.96%)
Earnings Announcements

Nabriva Therapeutics Provides Business Update And Announces Preliminary Financial Results For The Fourth Quarter Of 2021

Published: 01/10/2022 12:18 GMT
Nabriva Therapeutics Plc (NBRV) - Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021.
Nabriva Therapeutics Plc - Xenleta (lefamulin) Phase I Cystic Fibrosis (cf) Trial on Track to Enroll First Patient in Q122.
Nabriva Therapeutics Plc - Cash Resources of $47.7 Million As of December 31, 2021 Provides Cash Runway Well Into Q422.
Nabriva Therapeutics Plc - Sivextro(®) (tedizolid Phosphate) Remains on Track for Return to Historical Peak Sales by Mid-2022.
Revenue is expected to be $9.85 Million
Adjusted EPS is expected to be -$0.21

Next Quarter Revenue Guidance is expected to be $11.03 Million
Next Quarter EPS Guidance is expected to be -$0.19

More details on our Analysts Page.